ArticleClinical proteomics2026
The effect of preanalytical factors on cerebrospinal fluid and plasma proteomics: a systematic experimental study.
Article in Clinical proteomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPreanalytical variations (PAVs) are a major source of irreproducibility in biomarker studies. While their effects on blood have been widely examined, their impact on cerebrospinal fluid (CSF) proteomics remains less well characterized. We systematically evaluated common PAVs to inform biobanking and biomarker research.
methodsCSF and plasma samples were collected at an ISO 20387-accredited biobank. For each condition, three or four independent paired samples were analyzed. PAVs included storage temperature, processing delay, centrifugation speed, storage tube type, freeze-thaw cycles, and blood contamination. Protein abundance was quantified using SomaScan. Selected analytes were further evaluated using orthogonal immunoassays. Fold changes were calculated as linear RFU ratios relative to baseline. Paired t-tests with false discovery rate (FDR) correction were performed. Analytes showing detectable or larger changes were defined based on predefined fold-change thresholds with nominal p < 0.05.
resultsPlasma proteomes were highly sensitive to delays and temperature, with 969 analytes showing large changes after 24 h at 25 °C (counts refer to large changes), compared to 26 analytes in CSF. At 4 °C, CSF remained stable for 24 h (4 changes), whereas plasma showed extensive changes after 24 h (465) and 72 h (813). Storage at - 20 °C caused substantial shifts in both matrices (CSF: 144; plasma: 1,164), whereas no analytes differed in plasma stored at - 50 °C relative to - 80 °C. Freeze-thaw cycles up to three resulted in few altered analytes, whereas 11 cycles led to pronounced changes (CSF: 198; plasma: 21). Hemolysis in plasma induced 28 changes, whereas CSF blood contamination ≤ 500 cells/mm
conclusionsStorage temperature and processing delay were the most influential PAVs, with plasma more susceptible than CSF. For optimal quality, CSF should be processed within 4 h or kept at 4 °C, plasma within 2 h, and both stored at ≤ - 80 °C. Freeze-thaw cycles should be limited to three.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.